<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/280g–7b" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/280g–7b/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/280g–7b/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_280g_7b"><akn:num>280g–7b</akn:num><akn:heading>HHS public-private partnership for rare neurodegenerative diseases</akn:heading><akn:content><akn:p>§ 280g–7b. HHS public-private partnership for rare neurodegenerative diseases(a) EstablishmentNot later than one year after December 23, 2021, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall establish and implement a Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the Food and Drug Administration, and one or more eligible entities (to be known and referred to in this section as the “Partnership”) through cooperative agreements, contracts, or other appropriate mechanisms with such eligible entities, for the purpose of advancing the understanding of neurodegenerative diseases and fostering the development of treatments for amytrophic lateral sclerosis and other rare neurodegenerative diseases. The Partnership shall—(1) establish partnerships and consortia with other public and private entities and individuals with expertise in amyotrophic lateral sclerosis and other rare neurodegenerative diseases for the purposes described in this subsection;

(2) focus on advancing regulatory science and scientific research that will support and accelerate the development and review of drugs for patients with amyotrophic lateral sclerosis and other rare neurodegenerative diseases; and

(3) foster the development of effective drugs that improve the lives of people that suffer from amyotrophic lateral sclerosis and other rare neurodegenerative diseases.


(b) Eligible entityIn this section, the term “eligible entity” means an entity that—(1) is—(A) an institution of higher education (as such term is defined in section 1001 11 See References in Text note below. of title 20) or a consortium of such institutions; or

(B) an organization described in section 501(c)(3) of title 26 and exempt from tax under subsection (a) of such section;


(2) has experienced personnel with clinical and other technical expertise in the field of biomedical sciences and demonstrated connection to the patien</akn:p></akn:content><akn:subsection eId="subsec_280g_7b_a"><akn:num>(a)</akn:num><akn:heading>Establishment</akn:heading><akn:content><akn:p>(a) Establishment Not later than one year after December 23, 2021, the Secretary of Health and Human Services (referred to in this section as the “Secretary”) shall establish and implement a Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the Food and Drug Administration, and one or more eligible entities (to be known and referred to in this section as the “Partnership”) through cooperative agreements, contracts, or other appropriate mechanisms with such eligible entities, for the purpose of advancing the understanding of neurodegenerative diseases and fostering the development of treatments for amytrophic lateral sclerosis and other rare neurodegenerative diseases. The Partnership shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_280g_7b_b"><akn:num>(b)</akn:num><akn:heading>Eligible entity</akn:heading><akn:content><akn:p>(b) Eligible entity In this section, the term “eligible entity” means an entity that—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_280g_7b_c"><akn:num>(c)</akn:num><akn:heading>Gifts</akn:heading><akn:content><akn:p>(c) Gifts</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>